Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label ambrisentan study in pulmonary arterial hypertension
ACTRN12607000170426Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by Gilead Sciences. Primary endpoint: Change from baseline in 6-minute walk distance. Started Aug 2006; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on ACTRN12607000170426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000170426.